Inhibits growth and survival of malignant B-lymphocytes
Description
IBRULIEVA contains Ibrutinib, a first-generation Bruton’s Tyrosine Kinase (BTK) inhibitor. It blocks BTK signaling in B-cells, thereby inhibiting the growth and survival of malignant B-lymphocytes.
Key attributes
Category
ONCOLOGY
Brand
Allieva Pharma
Model number
IBRULIEVA 140MG
Place of origin
Lucknow, UP, India
Certificates
ISO 9001
WHO-GMP Certified Company
Reviews
Questions & answers
Ask the supplier — answers are visible to all buyers